Off-label or off-limits?

Nature Biotechnology

Volumn 26, Issue 8, 2008, Pages 867-875

  Ratner, Mark ^a   Gura, Trisha ^a  

^a FDC Windhover ^*

Author keywords

[No Author keywords available]

Indexed keywords

DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE SYSTEM; INSURANCE; MEDICARE; OFF LABEL DRUG USE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UNITED STATES;

DRUG APPROVAL; DRUG INDUSTRY; DRUG LABELING; DRUG UTILIZATION; FRAUD; GOVERNMENT REGULATION; HUMANS; MARKETING; PHYSICIAN-PATIENT RELATIONS; PRESCRIPTIONS, DRUG; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 49449092289     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0808-867     Document Type: Review

References (9)

1. Silverman, E. Amgen and Enbrel marketing: crossing another line? Pharmalot (February 6, 2008) 〈http://www.pharmalot.com/2008/02/ amgen-enbrel-marketing-crossing-another-line/〉
2. Radley, D.C. et al. Arch. Intern. Med. 166, 1021-1026 (2006).
3. Casali, P.G. Ann. Oncol. 18, 1923-1925 (2007).
4. BBC News. Tighter drug trial laws promised, March 6, 2008.
5. Conroy, S., Newman, C. & Gudka, S. Ann. Oncol. 14, 42-47 (2003).
6. Boos, J. Ann. Oncol. 14, 1-5 (2003).
7. Goldstein, J. The FDA contradicts Genentech on eye drug. The Wall Street Journal Health Blog (June 17, 2008) 〈http://blogs.wsj.com/ health/2008/06/17/fda-contradicts-genentech-on-eye-drug/〉
8. Avorn, J. & Soumerai, S.B. N. Engl. J. Med. 308, 1457-1463 (1983).
9. Avorn, J. et al. N. Engl. J. Med. 327, 168-173 (1992).